Boehringer Ingelheim GmbH
Binger Str. 173
96 articles with Boehringer Ingelheim GmbH
Empagliflozin reduced the combined relative risk of cardiovascular death and hospitalization for heart failure by 25 per cent in adults with and without diabetes who had heart failure with reduced ejection fraction
Empagliflozin also significantly reduced the relative risk of first and recurrent hospitalization for heart failure by 30 per cent and significantly slowed kidney function decline1
The company is expanding its capacity to make products that help protect pets from health problems
Boehringer Ingelheim and Lilly announce outcome of FDA Advisory Committee meeting for empagliflozin 2.5 mg as adjunct to insulin for adults with type 1 diabetes
The U.S. Food and Drug Administration Endocrinologic and Metabolic Drugs Advisory Committee voted 14 to 2 that the benefits of empagliflozin 2.5 mg do not outweigh the risks to support approval as an adjunct to insulin for adults with type 1 diabetes.
Alliance to focus combined expertise and investment to maximise Jardiance® for people with type 2 diabetes, heart failure, and chronic kidney disease
FDA Grants Ofev® Breakthrough Therapy Designation for Chronic Fibrosing ILDs with a Progressive Phenotype
The designation was supported by results from the Phase III INBUILD® study that met its primary endpoint and was recently published in the New England Journal of Medicine
Global professional services firm ZS has launched a strategic initiative with Boehringer Ingelheim to upgrade the top-20 pharmaceutical company's existing data and analytics system to a more flexible, efficient model with greater capacity for producing valuable customer insights.
Domain Therapeutics reaches two milestones in multi-target research collaboration with Boehringer Ingelheim
Less than one year after signing agreement, the GPCR expert has reached key discovery milestones in two independent projects
INBUILD® meets primary endpoint: study evaluated Ofev® in patients across a range of progressive fibrosing interstitial lung diseases
Boehringer Ingelheim announced that in the Phase III INBUILD® trial Ofev® slowed lung function decline by 57% across the overall study population, as assessed by the annual rate of decline in forced vital capacity over 52 weeks in patients with fibrosing interstitial lung diseases with signs of progression.
Closing of Financing Round and Strengthening of Development Team Paves the Way for T3 Pharma to Enter the Clinic
T3 Pharmaceuticals AG, a Basel-based company focusing on immuno-oncology, closes its second financing round of over 12M CHF with existing investors joined by Boehringer Ingelheim Venture Fund and Reference Capital SA.
Boehringer Ingelheim Payor Marketing and Sales and Agency Partner, The Kinetix Group, Win Marketing Team of the Year Gold Award at PM360 Trailblazer Awards
The Kinetix Group, a New York City-based life sciences marketing agency and care delivery consultancy, has been recognized by PM360 as the agency partner supporting Boehringer Ingelheim's win as Marketing Team of the Year.
50 million people worldwide live with symptomatic Alzheimer's, which has no cure. In honor of September 21st being World Alzheimer's Day, we evaluated the current therapies, drugs in the pipeline and disease outlook.
Law firm urges Zantac users to find out their rights against drug maker who knowingly sold potentially carcinogenic medication
With infection on the rise in people and pets, pet owners can take steps to protect their dogs
Boehringer Ingelheim and Zealand Pharma Advance Dual-Acting GLP-1/glucagon Agonist BI 456906 to Phase 2 Clinical Testing in Obesity/Diabetes
Boehringer Ingelheim and Zealand Pharma A/S, have announced that Boehringer Ingelheim plans to initiate Phase 2 development of the GLP-1/glucagon dual agonist BI 456906, which was in-licensed from Zealand.
North Carolina State University's Dr. Amy Stieler Stewart Recognized with the 2019 Boehringer Ingelheim Veterinary Graduate Award and Mariel Covo from University of Pennsylvania Receives the 2019 Boehringer Ingelheim Veterinary Research Scholar Award
Detailed findings from CAROLINA® outcome trial support long-term cardiovascular safety profile of Tradjenta®
CAROLINA® demonstrated no increased cardiovascular risk for Tradjenta® (linagliptin) versus glimepiride in the only active-comparator cardiovascular outcome trial for a dipeptidyl peptidase-4 (DPP-4) inhibitor
The U.S. Food and Drug Administration has accepted the New Drug Application for the investigational fixed-dose combination tablet of empagliflozin, linagliptin and metformin extended release for the treatment of adults with type 2 diabetes, Boehringer Ingelheim and Eli Lilly and Company announced.
Boehringer Ingelheim and Gubra announce new collaboration to develop anti-obesity peptide poly-agonists
Boehringer Ingelheim and Gubra announce a second collaboration and license agreement for the development of novel poly-agonist peptides to treat obesity.
Boehringer Ingelheim and Optimum Patient Care Launch First US Primary Care Patient Registry to Improve COPD Care
First-of-its-kind registry to exclusively focus on chronic obstructive pulmonary disease (COPD) treatment by primary care physicians
Boehringer Ingelheim announced the resolution of all intellectual property-related litigation with AbbVie concerning Cyltezo® (adalimumab-adbm) and the reference medicine Humira® (adalimumab).